Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo
NN9500-4656
Phase 2 small_molecule active
Quick answer
Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo for Non-alcoholic steatohepatitis (NASH) is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Non-alcoholic steatohepatitis (NASH)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active